PrimeRFP SCOUT · Federal Contract Recompete Brief

36C24523N0862Krystexxa 8mg — Horizon Therapeutics Usa, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Aug 28, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

245-Network Contract Office 5 (36C245)

Awarding office

Horizon Therapeutics Usa, Inc

Recipient

Aug 28, 2023

PoP end

$108K

Obligated

$108K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Federal

Contract number36C24523N0862

Also listed as36C245-23-N-0862

Also listed as36F79719D0224-36C24523N0862

Agency245-Network Contract Office 5 (36C245)

Awarding office245-Network Contract Office 5 (36C245)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentHorizon Therapeutics Usa, Inc

CAGE6TDL9

UEISK1UK7S74GB3

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79719D0224

Place of performanceLA VERGNE TN

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startAug 24, 2023

PoP end (current)Aug 28, 2023

Obligated$108K

Current value$108K

Potential value$108K

KRYSTEXXA 8MG is a federal award for 245-Network Contract Office 5 (36C245) held by Horizon Therapeutics Usa, Inc. Estimated value $108K ($108K obligated). Current period of performance ends Aug 28, 2023. Last award drew 1 bidder. Place of performance: LA VERGNE TN.

Recompete timing

Public

● Past PoP end (1130 days ago)

Current PoP ended Aug 28, 2023 (1130 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Bonuses end Sept 30

Want the durability read on 36C24523N0862? One Pursuit Analysis, $500, inside 48 business hours.

48 business hours
$500
Credits toward the Pack

Buy one Pursuit Analysis — $500

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C24523N0862?

36C24523N0862 (Krystexxa 8mg) is a 245-Network Contract Office 5 (36C245) award with a potential value of $108K, currently held by Horizon Therapeutics Usa, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C245-23-N-0862?

36C245-23-N-0862 is the dashed form of PIID 36C24523N0862 (Krystexxa 8mg), held by Horizon Therapeutics Usa, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C24523N0862?

245-Network Contract Office 5 (36C245) awarded 36C24523N0862 to Horizon Therapeutics Usa, Inc (potential $108K).

Who is the incumbent on 36C24523N0862?

Horizon Therapeutics Usa, Inc is the incumbent. The current period of performance ends Aug 28, 2023.

When does Horizon Therapeutics Usa, Inc’s 36C24523N0862 come up for recompete?

SCOUT tracks a period-of-performance end of Aug 28, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 36C24523N0862? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 24, 2023 · refreshed monthly